Core Viewpoint - Abbott reported quarterly earnings of 1.09pershare,exceedingtheZacksConsensusEstimateof1.07 per share, and showing an increase from 0.98pershareayearago,indicatingapositiveearningssurpriseof1.8710.36 billion for the quarter ended March 2025, which was below the Zacks Consensus Estimate by 0.56%, but up from 9.96billionyear−over−year[2]−Overthelastfourquarters,AbbotthassurpassedconsensusEPSestimatesthreetimesandtoppedrevenueestimatestwice[2]StockPerformance−Abbottshareshaveincreasedapproximately11.61.25 for the coming quarter and 5.15forthecurrentfiscalyear,alongsideexpectedrevenuesof11 billion and $44.42 billion respectively [7] - The estimate revisions trend for Abbott is currently mixed, resulting in a Zacks Rank 3 (Hold), suggesting shares are expected to perform in line with the market in the near future [6] Industry Context - The Medical - Products industry, to which Abbott belongs, is currently ranked in the bottom 25% of over 250 Zacks industries, indicating potential challenges ahead [8]